Title of the cohort

Aged 50 and over, residents in Zaragoza province

Acronym for cohort


Name of Principal Investigator
First name JESUS
Address of institution where award is held
InstitutionCARLOS III INSTITUTE OF HEALTH. National Centre of Epidemiology
Street AddressMonforte de Lemos 5, Pabellon 12




Contact email
Funding source


1. The cohort includes, or expects to include, incidence of the following conditions
  • Neurodegenerative disease in general
When studies on the above condition(s) are expected to become possible
2a. Stated aim of the cohort

1216 persons studied in 2008 and approximately the same will be studied by end of 2011

2b. Features distinguishing this cohort from other population cohorts

Strong emphasis on disability and health and social service development. WHO ICF methodology. Coverage of rural and urban populations. Cognitive and disability screened

3a. i) Number of publications that involve use of cohort to date


3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
Age in years from:>49 years
To (‘until death’ if applicable):
4b. Study criteria: inclusion criteria

residents for >1 year, aged >49 at recruitment

4c. Study criteria: exclusion criteria

No identification as person entitled to use of state run health care use.

5. Size of the cohort (i.e. number of participants enrolled)

1,000 – 5,000 participants

6a. Measures used to characterise participants

Cognitive and disability screenings were conducted using MMSE and the World Health Organization Disability Assessment Schedule. Participants screened positive for disability underwent an assessment protocol focusing on primary care diagnoses, disability, lifestyle, and social and health service usage.

6b. Additional measures for participants with a clinical disorder

No when no disability is recorded

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)


7. Study design

Cross sectional survey

8. Cases matched by
  • Other health assessment (specify) / N/A
  • No matching exists
9a. Does the study include a specialised subset of control participants


9b. If yes, description of specialised subset of control participants

Persons negative to disability screening or persons with only minor disability as per WHODAS-2 36

10a. i) Data collection start date


10a. ii) Data collection end date


10a iii) Data collection for this study is
  • Data collection ongoing
  • Data analysis ongoing
10b. Plans to continue the cohort study beyond the current projected end date
  • Yes – funding applied for
11. Data collected
  • Only through the study
  • Through links to medical records
  • Through links to other records or registers (such as dental records, police records etc). Please specify
  • prmary care computer fiels
12. System in place to enable re-contact with patients for future studies

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database
Yes/No% available
Data summarised in database YES 100%
Database is web-based NO
Database on spreadsheet NO
Database is on paper YES 80%
Other (specify)
Language used:


13b. Format and availability of data held as individual records
Yes/No% available
Data held as individual records YES 100
Data is web-basedNO
Data held on computer based records YES 100
Data held on cards
Other (specify)
Language used:


14a. Are data available to other groups


14b. Access policy/mechanisms for access if data are available to other groups
  • Other criteria (please specify)
  • When data at urban areas are available access may change
15. Data sharing policy specified as a condition of use

No policy exists

16a. Are tissues/samples/DNA available to other groups


16b. i) Description of available tissues/samples/DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
17. Is information on biological characteristics available to other groups
  • No

    Types: Population Cohorts
    Member States: Spain
    Diseases: Neurodegenerative disease in general
    Years: N/A
    Database Categories: N/A
    Database Tags: N/A

    Export as PDF